a pediatric pulmonologist and cystic fibrosis researcher at the University of California San Francisco who signed the letter, said it isn’t only patients overseas who can’t afford Trikafta.

FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 newly eligible U.S. patients. Suzetrigine for acute pain aligns with NOPAIN Act ...